Tuesday broker round-up
4th Jun 2019 13:55
(Sharecast News) - NewRiver: Berenberg downgrades to hold with a target price of 248p.
Read moreAstraZeneca searching for successor to chairman Johansson, reports say
4th Jun 2019 09:11
(Sharecast News) - AstraZeneca has begun the search for a new chairman as the role's current incumbent Leif Johansson looks set to end his seven year spell at the Anglo-Swedish outfit, according to a report from Sky News.
Read moreMonday broker round-up
3rd Jun 2019 12:07
(Sharecast News) - Ferguson: Peel Hunt upgrades to add with a target price of 5,430p.
Read moreTrials show AstraZeneca's Lynparza delaying pancreatic cancer progression
3rd Jun 2019 07:46
(Sharecast News) - AstraZeneca announced on Monday that its Lynparza pancreatic cancer drug has returned positive phase three trial results, doubling the amount of patients with no disease progression.
Read moreFriday broker round-up
24th May 2019 13:23
(Sharecast News) - SafeChange International Group: Berenberg downgrades to hold with a target price of 436p.
Read moreMonday broker round-up
13th May 2019 12:34
(Sharecast News) - Marks & Spencer: Citigroup upgrades to buy with a target price of 330p.
Read moreFriday broker round-up
10th May 2019 13:00
(Sharecast News) - Auto Trader: Citigroup downgrades to neutral with a target price of 580p.
Read moreAstraZeneca sees positives in latest roxadustat data
10th May 2019 07:29
(Sharecast News) - AstraZeneca announced top-line results from the pooled cardiovascular safety analyses of the global phase 3 programme for roxadustat on Friday, which its described as a first-in-class hypoxia-inducible-factor prolyl hydroxylase inhibitor.
Read moreDirector dealings: AstraZeneca CFO ups stake
8th May 2019 16:18
(Sharecast News) - AstraZeneca chief financial officer Marc Dunoyer purchased 8,500 ordinary shares in the FTSE 100-listed pharmaceuticals outfit on Tuesday.
Read moreAstraZeneca upbeat on latest results from potential breast cancer drug
8th May 2019 07:36
(Sharecast News) - AstraZeneca and its partner Daiichi Sankyo Company announced positive top-line results for the pivotal phase 2 'DESTINY-Breast01' trial of trastuzumab deruxtecan (DS-8201) on Wednesday.
Read moreAstraZeneca leukaemia drug trial reports positive results
7th May 2019 08:01
(Sharecast News) - AstraZeneca said a phase three trial of its Calquence treatment for chronic lymphocytic leukaemia had shown a "statistically-significant and clinically-meaningful improvement in progression-free survival" compared with a combination regimen.
Read moreAstraZeneca gets FDA approval for 'Qternmet XR'
3rd May 2019 07:27
(Sharecast News) - AstraZeneca announced on Friday that the US Food and Drug Administration (FDA) has approved 'Qternmet XR' (dapagliflozin, saxagliptin and metformin hydrochloride) extended release tablets as an oral adjunct treatment to diet and exercise, to improve glycaemic control in adults with type-2 diabetes (T2D).
Read moreTuesday broker round-up
30th Apr 2019 13:23
(Sharecast News) - Nexus: Numis downgrades to add with a target price of 165p.
Read moreMonday broker round-up
29th Apr 2019 13:25
(Sharecast News) - HomeServe: HSBC downgrades to reduce with a target price of 1,000p.
Read moreDeutsche stands by 'top pick' rating on AstraZeneca
29th Apr 2019 11:17
(Sharecast News) - Analysts at Deutsche Bank reiterated their 'buy' rating and 6,900p target price on British-Swedish pharmaceutical outfit AstraZeneca on Monday.
Read more